Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy

Inclusion Criteria: * More than or equal to 18 years old and less than 80 years old; * Acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) of the head; * Stroke onset within 24 hours and can be treated with study drug within 24 hours of symptoms onset； * The patient has received or is planning to receive vascular reperfusion therapy after onset； * Baseline NIHSS score is ≥4 and ≤26. * mRS ≤1 prior onset. * Informed consent signed. Exclusion Criteria: * Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.; * The acute infarcts lesion Involvement of more than one-third of middle cerebral artery (MCA) territory on initial brain imaging; * Rapidly improving symptoms at the discretion of the investigator; * Patients who have taken Dengzhanxixin Injection，edaravone or other brain protective drugs after onset ; * History of intracranial hemorrhage； * History of severe head trauma, stroke or myocardial infarction in past 3 months; * Diagnosised intracranial tumor and giant intracranial aneurysm； * Diagnosised aortic arch dissection； * Undergoing major surgery within 2 weeks prior to screening; or intracranial or intraspinal surgery within 3 months prior to screening; * Currently accompanied by active visceral bleeding; or arterial puncture at a site that is not easy to compress hemostasis within 1 week before screening; or gastrointestinal or urinary system bleeding occurred within 3 weeks before screening; * Those with acute bleeding tendency, including: platelet count \<100×109/L, combined with hemophilia, etc.; or those with partially activated thrombin time greater than 3 times the upper limit of normal; * Oral anticoagulants, and international normalized ratio\>1.7 or prothrombin time\>15s; * Diagnosed primary liver and kidney disease, AST or ALT (\>2 times the ULN), serum creatinine \>2.0mg/dL or \>176.8µmol/L; * Persistent blood pressure elevation ( systolic ≥180 mmHg or diastolic ≥100 mmHg ), despite blood pressure lowering treatment; * Those with a history of epilepsy or epilepsy-like symptoms at the onset of stroke; * Complete atrioventricular block; or according to the New York Heart Association (NYHA) cardiac function class II or above; or have been hospitalized due to congestive heart failure within 6 months before screening; * Pregnant women, nursing mothers, or reluctant to agree taking effective contraceptive measures during the period of trial subjects; * Those who have other neurological diseases or disabilities or mental diseases, which may affect the efficacy evaluation of this study as judged by the investigator; * Those with a history of malignant tumor within 5 years before screening (if the patient has basal cell carcinoma of the skin or carcinoma in situ of the cervix and has been cured, he/she can participate in this study); * Those who participated in other drug/device clinical studies and used the experimental drug/device within 3 months before screening; * Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study。